Suppr超能文献

使用粪便免疫化学检测参与基于人群的结直肠癌筛查可降低5年内的死亡率。

Participation in a population-based screening for colorectal cancer using the faecal immunochemical test decreases mortality in 5 years.

作者信息

Idigoras Rubio Isabel, Arana-Arri Eunate, Portillo Villares Isabel, Bilbao Iturribarrria Isabel, Martínez-Indart Lorea, Imaz-Ayo Natale, de la Cruz Marta, de Castro Visitación, López de Munain Arantza, Torrejón Perez Idoia, Gutiérrez-Ibarluzea Iñaki

机构信息

Basque Country Colorectal Cancer Screening Programme, Osakidetza, Basque Health Service.

Biocruces Health Research Institute, Barakaldo.

出版信息

Eur J Gastroenterol Hepatol. 2019 Feb;31(2):197-204. doi: 10.1097/MEG.0000000000001338.

Abstract

BACKGROUND

The steady increase in colorectal cancer (CRC) could be reversed through timely secondary prevention (screening) as a main strategy. The aims of this study were to determine the main features of CRC, survival rate and related factors for different types of identified CRCs in a population-based screening programme using the faecal immunochemical test (FIT).

MATERIALS AND METHODS

The CRCs in the susceptible population to be screened between 2009 and 2014 were identified and classified into four groups: (a) nonscreening-detected CRC (diagnosed before first screening invitation and nonparticipants), (b) screening-detected CRC, (c) interval cancer (IC) FIT (diagnosed between screening rounds after a negative FIT) and (d) IC colonoscopy (diagnosed before the colonoscopy surveillance, which is recommended after the screening colonoscopy). Patient demographics and epidemiological characteristics, tumour characteristics and survival were compared between the four groups.

RESULTS

5909 individuals were diagnosed with a CRC. The median follow-up of survival was 4.6 years (range: 0-9 years). The study highlights a significant difference (P<0.0001) in the 5-year survival in the screening-detected CRC group compared with those who had nonscreening-detected CRCs (90.1 vs. 66.7%). Although ICs are not desirable events, the 5-year survival rate is significantly higher with respect to nonparticipants (P<0.0001) (76.3 vs. 60.5%), this being the group with the lowest survival rate.

CONCLUSION

The significantly higher 5-year survival rate of 23.4% of the participants in the screening programme suggests that incidence and mortality rates of CRC will decrease in the near future for participants in screening programmes. A high participation rate is essential to achieve health benefits, irrespective of the type of participation.

摘要

背景

结直肠癌(CRC)发病率的持续上升可通过及时的二级预防(筛查)作为主要策略来逆转。本研究的目的是在一项基于人群的粪便免疫化学检测(FIT)筛查计划中,确定CRC的主要特征、生存率以及不同类型已确诊CRC的相关因素。

材料与方法

确定2009年至2014年间待筛查易感人群中的CRC,并将其分为四组:(a)非筛查发现的CRC(在首次筛查邀请前诊断且未参与者),(b)筛查发现的CRC,(c)间期癌(IC)FIT(在FIT阴性后的筛查轮次之间诊断),以及(d)IC结肠镜检查(在结肠镜监测前诊断,结肠镜监测是在筛查结肠镜检查后推荐的)。比较四组患者的人口统计学和流行病学特征、肿瘤特征及生存率。

结果

5909人被诊断患有CRC。生存的中位随访时间为4.6年(范围:0 - 9年)。该研究突出显示,筛查发现的CRC组与非筛查发现的CRC组相比,5年生存率存在显著差异(P<0.0001)(90.1%对66.7%)。尽管间期癌并非理想情况,但与未参与者相比,其5年生存率显著更高(P<0.0001)(76.3%对60.5%),未参与者的生存率是最低的一组。

结论

筛查计划中23.4%的参与者5年生存率显著更高,这表明筛查计划参与者的CRC发病率和死亡率在不久的将来将会降低。无论参与类型如何,高参与率对于实现健康益处至关重要。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验